Primary Care Evaluation of a Hepatitis C Virus (HCV) Screening Education Intervention

References

1. 1.↵
   1. Edlin BR,
   2. Eckhardt BJ,
   3. Shu MA,
   4. et al

   . Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (Baltimore, Md.) 2015;62:1353–63.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Hofmeister MG,
   2. et al

   . Estimating prevalence of hepatitis C virus infection in the United States. Hepatology 2018; 2013–2016.
3. 3.↵
   CDC. Hepatitis C Questions and answers for health professionals. 1/17/2019]; Available from: https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
4. 4.↵
   1. Smith BD,
   2. et al

   . Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012;61:1–32.

   OpenUrlPubMed
5. 5.↵
   1. Armstrong GL,
   2. Wasley A,
   3. Simard EP,
   4. et al

   . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–14.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Rein DB,
   2. Wittenborn JS,
   3. Weinbaum CM,
   4. et al

   . Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66–72.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Wenger PJ,
   2. Rottnek F,
   3. Parker T,
   4. et al

   . Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health 2014;104:1722–7.

   OpenUrl
8. 8.↵
   1. Ha S,
   2. Totten S,
   3. Pogany L,
   4. et al

   . Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57–62.

   OpenUrl
9. 9.↵
   1. Akiyama MJ,
   2. Kaba F,
   3. Rosner Z,
   4. et al

   . Correlates of hepatitis C virus infection in the targeted testing program of the New York City jail system: epidemiologic patterns and priorities for action. Public Health Rep 2017;132:41–7.

   OpenUrl
10. 10.↵
    1. Barth H

    . Hepatitis C virus: is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015;7:725–37.

    OpenUrlCrossRefPubMed
11. 11.↵
    CDC. Hepatitis C: by the numbers. 2020 8/17/2021]. Available from: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/Hepatitis-c-by-the-numbers.pdf.
12. 12.↵
    1. Schillie S,
    2. W C,
    3. Osborne M,
    4. Wesolowski L,
    5. Ryerson AB

    . CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020;69:1–17.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. El-Serag HB,
    2. Kanwal F,
    3. Richardson P,
    4. et al

    . Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology (Baltimore, Md.) 2016;64:p130–7.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Kanwal F,
    2. Kramer J,
    3. Asch SM,
    4. et al

    . Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996–1005.e1.

    OpenUrlCrossRef
15. 15.↵
    1. Backus LI,
    2. Belperio PS,
    3. Shahoumian TA,
    4. et al

    . Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2019;69:487–97.

    OpenUrl
16. 16.↵
    1. Tada T,
    2. Kumada T,
    3. Toyoda H,
    4. et al

    . Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol 2017;32:687–94.

    OpenUrl
17. 17.↵
    1. Wallerstein N,
    2. Duran B

    . Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. Am J Public Health 2010;100 Suppl 1:S40–6.

    OpenUrlPubMed
18. 18.↵
    1. Israel BA,
    2. Schulz AJ,
    3. Parker EA

    , Community-Campus Partnerships for Healthet al. Community-based participatory research: policy recommendations for promoting a partnership approach in health research. Educ Health (Abingdon) 2001;14:182–97.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Tapp H,
    2. Ludden T,
    3. Shade L,
    4. et al

    . Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system. Prev Med Rep 2020;17:101036.

    OpenUrl
20. 20.↵
    1. de Hoop E,
    2. van der Tweel I,
    3. van der Graaf R,
    4. et al

    . The need to balance merits and limitations from different disciplines when considering the stepped wedge cluster randomized trial design. BMC Med Res Methodol 2015;15:93.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Prost A,
    2. Binik A,
    3. Abubakar I,
    4. et al

    . Logistic, ethical, and political dimensions of stepped wedge trials: critical review and case studies. Trials 2015;16:351.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Ludden T,
    2. Shade L,
    3. Thomas J,
    4. et al

    . Novel models to identify census tracts for hepatitis C screening interventions. J Am Board Fam Med Med 2020;33:407–16.

    OpenUrl
23. 23.↵
    1. Hooper R,
    2. Teerenstra S,
    3. de Hoop E,
    4. et al

    . Sample size calculation for stepped wedge and other longitudinal cluster randomised trials. Stat Med 2016;35:4718–28.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Al-Hihi E,
    2. Shankweiler C,
    3. Stricklen D,
    4. et al

    . Electronic medical record alert improves HCV testing for baby boomers in primary care setting: adults born during 1945–1965. BMJ Open Quality 2017;6:e000084.

    OpenUrl
25. 25.↵
    1. Hemker BG,
    2. Brousseau DC,
    3. Yan K,
    4. et al

    . When children with sickle-cell disease become adults: lack of outpatient care leads to increased use of the emergency department. Am J Hematol 2011;86:863–5.

    OpenUrlCrossRefPubMed